在职业暴露与认知功能之间的关联中,陶酸基位的适度调解
Yujun Ma1, Guangsen Feng1, Shihui Guo1
1Department of Occupational Health, School of Public Health, MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University, Taiyuan, Shanxi 030001, China.
Neurotoxicology
|November 20, 2025
概括
职业暴露与认知能力下降和酸化 (P-tau) 水平增加有关,特别是P-tau231. 合成因子,如PP2A,显著调解这种关系,表明干预的目标.
科学领域:
- 神经科学是一个神经科学.
- 职业健康 职业健康 职业健康
- 生物化学 生物化学
背景情况:
- 职业暴露是神经退行性疾病的潜在危险因素.
- 化陶 (P-tau) 是认知障碍的一个关键生物标志物.
- 了解蛋白合成和降解的途径对于神经保护至关重要.
研究的目的:
- 研究职业暴露,血P-tau水平 (P-tau181,P-tau231) 和认知功能之间的关联.
- 探索P-tau的调解作用和合成/降解因子在引起的认知障碍中的调节作用.
主要方法:
- 208名工厂工人进行了等离子体,认知表现 (MMSE等) 的评估. ),以及血中的P-tau181/P-tau231.1.
- 进行了调解和调节调解分析,以检查暴露,P-tau,认知得分和tau途径生物标志物 (PP2A,CDK5,CHIP,Ub) 之间的关系.
主要成果:
- 血度升高与认知功能低下和P-tau181/P-tau231水平升高相关.
- P-tau231显著调解了暴露与认知衰退 (35.9%) 之间的关联.
- 陶氏合成因子,特别是PP2A,对P-陶氏介导的认知障碍途径表现出比降解因子更明显的缓解作用.
结论:
- 职业暴露会对认知功能产生负面影响,部分是通过P-tau升高,特别是P-tau231.
- P-tau231和PP2A途径是相关认知障碍早期干预和生物监测的关键目标.
- 研究结果为职业健康风险管理和神经保护策略提供了洞察力.
相关概念视频
Alzheimer's Disease: Overview
1.6K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
1.6K
Alzheimer's Disease: Treatment
772
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
772


